WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the launch of WuXia293Stable, a new platform designed for the development and manufacturing of innovative, difficult-to-express molecules that are stably expressed in HEK293 cells.
The platform, which demonstrates high titers, robust stability and superior quality, significantly enhances the developability and manufacturability of these molecules, offering a highly efficient CMC solution for biologics that are sophisticated in both structure and function.
The platform achieves a fed-batch titer of up to 5.0 g/L for monoclonal antibodies while significantly improving purity. WuXia293Stable offers flexible scalability in culture scale to meet the diverse needs of various research and pre-clinical development stages.
Furthermore, the WuXia293Stable cell line maintains stable expression and consistent quality during long-term cell passages, enabling scalable clinical and commercial manufacturing at 2000L scale for fed-batch and 1000L scale for perfusion. Moreover, WuXi Biologics offers a comprehensive suite of services for the WuXia293Stable platform, including cell bank testing and viral clearance validation as part of its one-stop CMC solution.
The launch of the WuXia293Stable platform has further strengthened the service capabilities of WuXi Biologics' WuXia™ platform family. Besides WuXia293stable, the WuXia™ platform has already derived multiple cell line development platforms, including WuXiaADCC Plus™ and WuXia RidGS™, to address customers' diverse requirements.
